Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 819.36 USD 0.9% Market Closed
Market Cap: 776.5B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is 311.95 USD. Compared to the current market price of 819.36 USD, Eli Lilly and Co is Overvalued by 62%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
Base Case
311.95 USD
Overvaluation 62%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

15.8
P/S
P/S
Price to Sales
15.8
vs History
30
vs Industry
9
Median 3Y
15.7
Median 5Y
11.2
Industry
2.6
Forward
12.9
More Details
69.9
P/E
P/E
Price to Earnings
69.9
vs History
30
vs Industry
5
Median 3Y
69.3
Median 5Y
53
Industry
21.5
Forward
37.5
More Details
83.3
P/OCF
P/OCF
Price to OCF
83.3
vs History
28
vs Industry
5
Median 3Y
81.9
Median 5Y
41.6
Industry
16.6
More Details
70.6
P/FCFE
P/FCFE
Price to FCFE
70.6
vs History
36
vs Industry
5
Median 3Y
84.2
Median 5Y
59.5
Industry
24
More Details
49.3
P/B
P/B
Price to Book Value
49.3
vs History
25
vs Industry
0
Median 3Y
47.4
Median 5Y
35.3
Industry
2.1
More Details
16.5
EV/S
EV/S
Enterprise Value to Sales
16.5
vs History
28
vs Industry
8
Median 3Y
16.3
Median 5Y
11.6
Industry
2.7
Forward
13.5
More Details
20.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
20.2
vs History
30
vs Industry
9
Median 3Y
20
Median 5Y
15.2
Industry
5.3
More Details
37.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
37.5
vs History
38
vs Industry
7
Median 3Y
47.2
Median 5Y
33.5
Industry
12.8
Forward
31
More Details
41
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
41
vs History
41
vs Industry
8
Median 3Y
54.1
Median 5Y
37.1
Industry
16.2
Forward
33.5
More Details
86.7
EV/OCF
EV/OCF
Enterprise Value to OCF
86.7
vs History
26
vs Industry
5
Median 3Y
85.3
Median 5Y
43.4
Industry
14.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
0
Median 3Y
48.6
Median 5Y
44.5
Industry
17.7
More Details
9.8
EV/IC
EV/IC
Enterprise Value to IC
9.8
vs History
28
vs Industry
8
Median 3Y
9.7
Median 5Y
7.3
Industry
1.9
More Details

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
NYSE:LLY
776.5B USD 15.8 69.9 37.5 41
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
377.9B USD 4.2 17.3 12.7 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 7.6 21.9 15.1 17.3
CH
Roche Holding AG
SIX:ROG
214.5B CHF 3.5 25.9 9.7 11.4
CH
Novartis AG
SIX:NOVN
190.4B CHF 4.4 18.3 10.7 14.4
UK
AstraZeneca PLC
LSE:AZN
170.3B GBP 4.2 29.7 131.4 198.1
US
Merck & Co Inc
NYSE:MRK
205.6B USD 3.2 11.8 8.8 10.6
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
139.5B USD 2.2 17.7 7.6 10.7
FR
Sanofi SA
PAR:SAN
108.8B EUR 1.2 8.6 4.7 5.6
P/E Multiple
Earnings Growth PEG
US
Eli Lilly and Co
NYSE:LLY
Average P/E: 24.6
69.9
50%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.3
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
21.9
18%
1.2
CH
Roche Holding AG
SIX:ROG
25.9
32%
0.8
CH
Novartis AG
SIX:NOVN
18.3
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.7
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.8
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.7
31%
0.6
FR
Sanofi SA
PAR:SAN
8.6
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBITDA: 395.1
37.5
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.7
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
13%
1.2
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.7
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.4
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.8
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
FR
Sanofi SA
PAR:SAN
4.7
7%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBIT: 1 698.5
41
32%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.6
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
17.3
14%
1.2
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
CH
Novartis AG
SIX:NOVN
14.4
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
198.1
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.6
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.7
10%
1.1
FR
Sanofi SA
PAR:SAN
5.6
14%
0.4

See Also

Summary
LLY intrinsic value, competitors valuation, and company profile.
DCF Valuation
LLY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LLY stock valuation using valuation multiples.
Wall Street Estimates
LLY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LLY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 261,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.